Voluntis earned the CE Mark for a new version of Insulia, a software application that recommends insulin doses for adults with Type 2 diabetes.

The new version of the app incorporates intermediate-acting neutral protamine Hagedorn (NPH) insulin — a type of insulin sometimes recommended as a first-line treatment, often requiring twice-daily injections.

The app can be loaded onto a smart phone or accessed by a computer via a web portal. Insulia also allows the prescribing doctor to monitor the patient’s progress and can help NPH insulin patients “reduce day-to-day challenges,” the company said.